Part D Senior Savings Model

On September 29, 2021, CMS announced the CY 2022 Part D plan sponsor participants in the Part D Senior Savings Model. See CY 2022 Model Participation section below for additional information.

Note for people with Medicare: Visit Medicare.gov to find information on how you can get insulin savings through the Part D Senior Savings Model, or call 1-800-MEDICARE (1-800-633-4227). TTY users can call 1-877-486-2048.

Through the Part D Senior Savings Model (or the “Model”), the Centers for Medicare & Medicaid Services (CMS) is testing the impact of offering beneficiaries an increased choice of enhanced alternative Part D plan options that offer lower out-of-pocket costs for insulin. The voluntary Model began on January 1, 2021, and will continue for five years, through December 31, 2025. The Model’s test contributes to the modernization of the Part D benefit and enhanced access to prescription drugs for Medicare beneficiaries.

Background

One in every three Medicare beneficiaries has diabetes, and over 3.3 million Medicare beneficiaries use one or more of the common forms of insulin. For some of these beneficiaries, access to insulin can be a critical component of their medical management, with gaps in access increasing risk of serious complications, ranging from vision loss to kidney failure to amputation to heart attacks. Unfortunately, sometimes the cost of insulin can be a barrier to appropriate medical management of diabetes.

The Centers for Medicare & Medicaid Services (CMS) Part D Senior Savings Model (or the “Model”) is designed to provide Medicare beneficiaries with new choices of Part D plans that offer insulin at an affordable and predictable cost where a one-month supply of a broad set of plan-formulary insulins costs no more than $35 each.

Details on pharmaceutical manufacturer and Part D sponsor Model participation can be found below.

Model Details

CMS is testing a change to the Medicare Coverage Gap Discount Program (the “discount program”) to allow participating Part D sponsors, through eligible enhanced alternative plans, to offer a Part D benefit design that includes predictable copays in the deductible, initial coverage, and coverage gap phases. The Model does this by offering supplemental benefits that apply after manufacturers provide a discounted price for a broad range of insulins included in the Model. The Model does not change cost sharing in the catastrophic phase.

The Model aims to reduce Medicare expenditures while preserving or enhancing quality of care for beneficiaries, and offers additional Part D plan choices to beneficiaries who receive Part D coverage through standalone Prescription Drug plans (PDPs) or those who receive Part D coverage through Medicare Advantage, Prescription Drug plans (MA-PDs). These Model-participating plan benefit packages (PBPs) will provide stable, predictable copays for certain insulins throughout the different phases of the Part D benefit.

Specifically, CMS is enabling health plan innovation to offer beneficiaries lower prescription drug out-of-pocket costs by waiving a requirement that is currently a programmatic disincentive for Part D sponsors to design prescription drug plans that offer supplemental benefits to lower beneficiary cost sharing in the coverage gap phase of the Part D benefit for certain insulins.

While under the current law, outside the Model, Part D sponsors may offer supplemental benefits to lower beneficiary cost sharing through the coverage gap phase of the Part D benefit, they often chose not to do so because such benefits would reduce the amount of coverage gap discounts the pharmaceutical manufacturers would otherwise pay. Those costs, which would accrue to the plan, would then be passed on to beneficiaries in the form of higher supplemental premiums.

Because Part D sponsors compete to offer Medicare beneficiaries affordable prescription drug coverage, only a few sponsors design a benefit that has supplemental benefit coverage for brand or other applicable drugs in the coverage gap. Brand and other applicable drugs are the set of medications that often cost beneficiaries the most, and beneficiaries in the coverage gap phase pay 25 percent of the negotiated price, which may closely mirror the medication’s list price. That amount is often significantly higher than in the initial coverage phase and can represent a financial burden for Medicare beneficiaries.

Under the Model, which began on January 1, 2021, CMS is testing a change where Part D sponsors that participate in the Model offer beneficiaries prescription drug plans that provide supplemental benefits for a broad range of insulins in the coverage gap phase of the Part D benefit. Participating pharmaceutical manufacturers will pay the 70 percent discount in the coverage gap for the Part D insulins they market, but those manufacturer discount payments would now be calculated before the application of supplemental benefits under the Model.

Part D sponsors participating in the Model will offer beneficiaries plan choices that provide broad access to multiple types of insulin, marketed by Model-participating pharmaceutical manufacturers, at a maximum copay of $35 each for a month’s supply in the deductible, initial coverage, and coverage gap phases of the Part D benefit. As a result, beneficiaries who take insulin and enroll in a plan participating in the Model should save an average of $446 in annual out-of-pocket costs on insulin, or over 66 percent, relative to their average cost-sharing today. This predictable copay will provide improved access to and affordability of insulin in order to improve management of beneficiaries who require insulin as part of their care.

To encourage broad Part D sponsor participation, CMS is providing Part D sponsors the option of additional risk corridor protection for Calendar Year (CY) 2021 and CY 2022 for PBPs that have higher enrollment than average from insulin-dependent diabetic patients, when the PBP meets qualifying criteria. Through the Model, CMS is also testing how participating Part D sponsors may best encourage healthy behaviors and medication adherence through Part D Rewards and Incentives programs.

CY 2022 Model Participation

CY 2022 Participating Pharmaceutical Manufacturers

CMS released the CY 2022 Request for Applications for Pharmaceutical Manufacturers for the Part D Senior Savings Model in January 2021. Completed applications, including a signed Addendum to the Medicare Coverage Gap Discount Program Agreement for Participation in the Part D Senior Savings Model, were due to CMS by January 27, 2021. Manufacturers that were approved to participate in CY 2021 will continue to participate in CY 2022.

The following pharmaceutical manufacturers are participating in the Part D Senior Savings Model for CY 2022:

  • Eli Lilly and Company
  • MannKind Corporation
  • Mylan Specialty L.P., a Viatris Company
  • Novo Nordisk, Inc. and Novo Nordisk Pharma, Inc.
  • Sanofi-Aventis U.S. LLC

Please see the list of Model drugs (PDF) for CY 2022 for more information. Please note that there is a separate list of CY 2021 Model Drugs for CY 2021. Part D Sponsor participants for CY 2021 who are looking to make formulary updates in 2021 should use the CY 2021 Model Drug List.

CY 2022 Participating Part D Plan Sponsors

Part D sponsors had the opportunity to apply for CY 2022 participation by April 12, 2021. CMS received significant interest in the Model from Part D sponsors, and will continue to have robust participation in the Model for CY 2022. Across the nation, CMS anticipates that 2,159 prescription drug plans, including both Medicare Advantage, Prescription Drug plans (MA-PDs) and standalone Prescription Drug plans (PDPs), will participate in the Part D Senior Savings Model for CY 2022. One hundred and six (106) Part D sponsors are participating in the Model for CY 2022. Seniors who use insulin in all 50 states, D.C., and Puerto Rico have a choice of a Part D Senior Savings Model participating plan in their area in CY 2022.

Beneficiaries will be able to find and compare prescription drug plans for the 2022 plan year, including plans that are participating in the Part D Senior Savings Model, through the Medicare Plan Finder on Medicare.gov during the annual open enrollment period. CMS is posting a list of Part D Senior Savings Model Plan Participants at a state and county level (see “2022 Part D Senior Savings Model Landscape File” file below).

  • 2022 Medicare Open Enrollment Information: As part of open enrollment, CMS has created a partner toolkit with information about the Part D Senior Savings Model, including how to identify and select the best Part D plan option based on a beneficiary's current prescription drugs. More information is available HERE.
  • 2022 Part D Senior Savings Model Landscape File (XLS): Use this spreadsheet to search states and counties for Part D Senior Savings Model participating plans.

The following materials are applicable for CMS-approved Part D Sponsors participating in the Part D Senior Savings Model for CY 2022. 

CY 2021 Model Participation

CY 2021 Participating Pharmaceutical Manufacturers

On March 23, 2020, CMS announced broad pharmaceutical manufacturer participation for the insulins to be offered in CY 2021. The following pharmaceutical manufacturers are participating in the Part D Senior Savings Model for CY 2021:

  • Eli Lilly and Company
  • Novo Nordisk, Inc. and Novo Nordisk Pharma, Inc.
  • Sanofi-Aventis U.S. LLC

Please see the list of Model drugs (PDF) for CY 2021 below for more information.

CY 2021 Participating Part D Plan Sponsors

Part D sponsors had the opportunity to apply for CY 2021 participation by May 1, 2020. CMS received significant interest in the Model from Part D sponsors, and has robust participation in the Model for CY 2021. Across the nation, 1,635 prescription drug plans, including both Medicare Advantage, Prescription Drug plans (MA-PDs) and standalone Prescription Drug plans (PDPs), are participating in the Part D Senior Savings Model for CY 2021. Seventy-six (76) Part D sponsors are participating in the Model for CY 2021, covering more than 13.8 million total enrollees. CMS estimates that the Model’s supplemental benefits will be directly available to more than 650,000 enrollees who use insulin and are enrolled in a participating plan for CY 2021. Seniors who use insulin in all 50 states, D.C., and Puerto Rico have a choice of a Part D Senior Savings Model participating plan in their area in CY 2021.

Beneficiaries were able to find prescription drug plans for the 2021 plan year, including plans participating in the Part D Senior Savings Model, through the Medicare Plan Finder on Medicare.gov during the annual open enrollment period. CMS posted a list of Part D Senior Savings Plan Model Participants at a state level (see “2021 Part D Senior Savings Model Landscape File” file below).

The following materials are applicable for CMS-approved Part D Sponsors participating in the Part D Senior Savings Model for CY 2021. 

For questions relating to the Part D Senior Savings Model, please email PartDSavingsModel@cms.hhs.gov.

CY 2022 Materials

Additional Information

CY 2021 Materials

Last updated on:
09/30/2021